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Objectives: Next Generation Sequencing (NGS) offers a potentially powerful plat-
form for extremely sensitive, high-throughput, multiplex, quantitative detection of 
nucleic acid biomarkers. While NGS currently represents a small portion of global 
clinical molecular diagnostic testing, new funding and reimbursement initiatives 
promise to accelerate its clinical utilization. Given increasing numbers of predic-
tive/ prognostic biomarkers but limited tissue and need for less invasive sample 
acuisition, NGS has the potential to transform personalized medicine (PM) and 
companion diagnostics. The current study characterized global NGS availability and 
reimbursement trends. Health technology assessments (HTAs) for NGS and other 
relevant multiplex/ gene panel tests were also studied for evolving evidence require-
ments. MethOds: Key health care provision, HTA agency, and payer websites in the 
EU, US, Australia and Canada were reviewed to identify NGS funding and reimburse-
ment initiatives, and relevant HTAs. In addition, a limited number of stakeholder 
interviews were conducted to help further characterize the evolving global NGS 
landscape. Results: A number of NGS funding and reimbursement initiatives 
were identified, especially France, Germany, UK, US and Australia. Initiatives have 
been mainly centered on funding of pilot clinical utility demonstrations through 
research and clinical use. In Germany and US, specific initiatives are underway to 
develop specific NGS reimbursement codes and payment rates. A number of HTAs 
for NGS and other multiplex/ gene panel test platforms were identified, primarily for 
oncology, cardiovascular, infectious disease, inherited disease, and neuropsychiatry 
applications. Key HTA concerns include test clinical utility, cost-effectiveness, real-
world reproducibility and equity of access given potential cost. cOnclusiOns: 
Payers and providers increasingly recognize NGS as enabling expanded adoption 
of PM approaches. As PM expands with increasing numbers of clinically actionable 
biomarkers, ensuring that test evidence development is aligned with expectations, 
and expectations with reality are key steps. Further, developing reimbursement/ 
funding mechanisms to support testing uptake will be critical in all markets.
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By 2030, 50% of all deaths are expected to be caused by oncology, or cardiovascular 
diseases. Research and development therefore continues to evolve in these areas to 
provide a better answer to complex medical needs. As a consequence, the definition 
of innovation is evolving, going from therapeutic drugs with a new mode of action 
to novel biotechnologies, biological therapeutics, and vaccination. Objectives: 
We aim to investigate how therapies for oncology and cardiovascular diseases are 
expected to evolve in future into technologies that transform the concept of innova-
tion. MethOds: Data were extracted from Citeline to assess the scale of therapies 
in development including: vaccines, stem cells, antibodies, reformulation of combi-
nation therapy, gene therapy and RNAi. Results: In oncology, across the selected 
novel therapies, there are over 670 trials in preclinical to phase 3 of development. 
Vaccines have a higher rate of development with over 200 products in preclinical 
development to phase 3. Other areas of development include antibodies, and gene 
therapy, with over 30 therapies in phase 2 trials alone. Meanwhile, cardiovascular 
disease has fewer ongoing ‘novel therapy’ trials compared to oncology (around 75% 
fewer trials). The main areas of development include reformulation of fixed dose 
combinations, and stem cell research (a total of 60 trials, and 53 trials in preclinical 
to phase 3 respectively). The trend in innovation for cardiovascular disease instead 
tends to be focussed on integrated technology and medical devices. cOnclusiOns: 
While we are fairly acquainted with the current evaluation methods and relevance 
of clinical and economic evidence of traditional therapies, the emergence of new 
technologies creates uncertainties around how they will be assessed by payers. For 
example, demonstrating the value of vaccines (which avoid illness) is difficult to 
express. Industry must now consider factors outside of the current remit to prepare 
for successful market access.
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Objectives: It is controversial to use 5-year survival estimates to assess the pro-
gress in cancer prevention and control. The study aimed to analyze associations 
between 5-year survival, and two standard measures of cancer burden, incidence 
and mortality, based on publicly available population cancer statistics in England 
and Wales. MethOds: Sex-specific mortality and incidence of 14 types of com-
mon cancer between 1976 to 1995 were obtained from a national database on 
the UK Office for National Statistics website. Sex-specific 5-year survival data 
retrieved from the Cancer Research UK website databases. The relationships 
between 5-year survival, and incidence and mortality were estimated based on 
both Pearson and Spearman correlation coefficients. Results: From 1976 to 1995, 
all male and female cancer types showed increased 5-year survival, ranged from 
0.2% (pancreas and lung cancers) to 16.6% (prostate cancer) for males, and from 
Objectives: Colorectal cancer (CRR) is an important public health problem. The 
human and financial costs of this disease have prompted considerable research 
efforts to evaluate the ability of screening tests to detect the colorectal cancer at 
an early curable stage. It is now established that screening by faecal occult blood 
test (FOBT) in average-risk populations can detect asymptomatic colorectal cancers 
and precancerous lesions (high-risk adenomas). MethOds: We have reviewed the 
evidence about the quality, accessibility, and cost of screening using the FOBT to 
reduce colorectal cancer mortality. Such databases as Medline, PubMed, EMBASE 
were used. Results: Faecal occult blood test screening benefits include reduc-
tion in CRR mortality, possible reduction in cancer incidence through detection 
and removal of colorectal adenomas and potentially, treatment of early colorectal 
cancers may involve less invasive surgery. Thus, implementation of biennial faecal 
occult blood test screening is an efficient use of health resources. cOnclusiOns: 
The main objective for the improvement of cancer patients’ care is the introduction 
of national colorectal cancer screening programs based on evidence and available to 
people across the country. Introduction of clinical and cost-effectiveness screening 
methods in Ukraine and coordination of Ukrainian and world practices will provide 
timely and effective medical care for patients with CRR. In order to integrate these 
approaches into clinical practice based on evidence the clinical protocols are being 
developed.
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bAckgROund: There is ongoing debate over the extension of accelerated 
approval and conditional market authorisation initiatives, particularly for 
new cancer drugs in the US and Europe. This raises concerns for the benefit-
risk assessments of both regulators and payers when relying on early trial 
evidence. Methodological issues relating to immature clinical data and 
short-term follow-up, as well as the potential use of surrogate endpoints, 
may undermine these assessments and the resulting decisions made under 
conditions of uncertainty. In the context of health technology assessments 
(HTA) in the UK, we considered the impact on the probabilities of being the 
most effective and cost-effective treatment when reviewing available evi-
dence along the drug development and assessment processes. Objectives: 
To conduct a retrospective analysis of four NICE technology appraisals in pri-
mary breast cancer for HER-2 positive women alongside a simulation study to 
evaluate the relative effectiveness and cost-effectiveness of selected drugs over 
time. MethOds: We extracted data from TA107, TA108, TA109 and TA112 to ana-
lyse ‘snapshots’ of evidence at different time-points. Based on this example, we 
simulated individual patient characteristics and progression-free survival (PFS) 
times according to a predefined recruitment timeline. For both applied and simu-
lated datasets, we combined a network-meta-analysis and three-stage Markov 
economic model in WinBUGS to predict the joint impact of growing evidence net-
works on HTA results. The model allowed for different assumptions regarding the 
extrapolation of and the correlation between PFS and overall survival. Results: 
The magnitudes of credible intervals depended heavily upon the level of restriction 
used for follow-up. In addition, the performance of PFS as a surrogate endpoint 
strongly relied on the assumptions made on the correlation between the two 
endpoints. cOnclusiOns: Our analysis highlighted the inherent limitations and 
risks of early assessments with a substantial increase in the uncertainty of treat-
ment acceptability at thresholds of £20K and £30K.
PCN214
exPert eliCitatioN uSed For early teChNoloGy aSSeSSmeNt to iNForm 
oN CoSt-eFFeCtiveNeSS oF Next GeNeratioN SequeNCiNG
Retèl V.P.1, Joosten S.E.1, van Harten W.H.2
1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2University of Twente, Enschede, The 
Netherlands
Objectives: Next Generation Sequencing (NGS) promises to find mutations 
(targets) in individual cancer patients, to subsequently assign targeted therapy. 
Currently, the technology itself is still in development and the effects on disease 
development, prognosis, or choice of therapy are still unclear. Besides informa-
tion for the current patient, additional (secondary) information for future patients 
can also become available. To accelerate the reimbursement process and have a 
NGS-panel available for patients in the earliest possible stage, early Technology 
Assessment (TA) is ongoing. In this project, we report on expert elicitation by 
means of scenario drafting, to provide qualitative and quantitative data to fill 
the evidence gaps in early cost-effectiveness modeling. MethOds: The follow-
ing steps in a multi-parameter framework can be distinguished: 1) Identifying 
(dynamic) aspects having impact on adoption; 2) Brainstorm on possible sce-
narios (informal interviews with NGS experts); 3) Scenario construction; 4) 
Validation of scenarios (semi-structured questionnaires to European NGS-experts); 
5) Quantification into parameters for cost-effectiveness modeling. Results: 
Based on the interviews and questionnaires (n= 29), the most likely scenarios as 
patients interest in NGS (likelihood 66,5% ±28,1); organizational readiness (84,4 
±18,5); advantage of including RNA, and the demand from the clinic (needs of 
medical staff) were identified as drivers for NGS development. Possible barrier 
scenarios were: number of actionable targets (55,2 ±23,7); demonstrating clinical 
utility (50,4 ±31,4); current evidence generation (65,5 ±27,9); consensus on panel 
for reimbursement (40,3% ±24,1); and competition within the field (64,2 ±21,9). 
Clustering into parameters for cost-effectiveness modeling resulted in: “failures”, 
“compliance”, “uptake”, and “future information”. cOnclusiOns: Although there 
are many issues to overcome to adopt NGS, the likelihood of NGS incorporation in 
clinical practice is very high. The “additional future information” is the most inter-
esting but complex variable to identify and to incorporate in cost-effectiveness 
modeling.
